| Literature DB >> 26286058 |
Gautom Kumar Das1, Noah J J Johnson1, Jordan Cramen1, Barbara Blasiak2, Peter Latta2, Boguslaw Tomanek2, Frank C J M van Veggel1.
Abstract
A major limitation of the commonly used clinical MRI contrast agents (CAs) suitable at lower magnetic field strengths (<3.0 T) is their inefficiency at higher fields (>7 T), where next-generation MRI scanners are going. We present dysprosium nanoparticles (β-NaDyF4 NPs) as T2 CAs suitable at ultrahigh fields (9.4 T). These NPs effectively enhance T2 contrast at 9.4 T, which is 10-fold higher than the clinically used T2 CA (Resovist). Evaluation of the relaxivities at 3 and 9.4 T show that the T2 contrast enhances with an increase in NP size and field strength. Specifically, the transverse relaxivity (r2) values at 9.4 T were ∼64 times higher per NP (20.3 nm) and ∼6 times higher per Dy(3+) ion compared to that at 3 T, which is attributed to the Curie spin relaxation mechanism. These results and confirming phantom MR images demonstrate their effectiveness as T2 CAs in ultrahigh field MRIs.Entities:
Keywords: contrast agents; dysprosium; high-field MRI; lanthanide nanoparticles; relaxivity
Year: 2012 PMID: 26286058 DOI: 10.1021/jz201664h
Source DB: PubMed Journal: J Phys Chem Lett ISSN: 1948-7185 Impact factor: 6.475